Feature|Videos|July 18, 2024
Streamlining Rare Disease Drug Development
The discussion explores how the principles of Operation Warp Speed can be applied to expedite rare disease therapeutic development through a new FDA pilot program aimed at streamlining the drug development process.
Advertisement
Episodes in this series
The conversation centered around the potential of mRNA technology for therapeutic development, with a focus on project management, meeting efficiency, and the challenges of mRNA production.
Discussion Topics
- 00:00 - Core aspects of CMC for mRNA as a shared platform for cGMP compliance
- 2:17 - Adapting mRNA manufacturing processes to quickly produce vaccine variants
- 5:18 - Differences in quality and purity of mRNA products from various manufacturers
- 6:12 - Developing guidelines to accelerate rare disease drug development, similar to Operation Warp Speed
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
2
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
3
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
4
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
5
